Purpose The aim of the study was to assess the validity, reliability and sensitivity of the FACT-P (version 4) in Chinese males with prostate cancer. Methods Construct validity was assessed using Spearman's correlation test against the 12-item Short Form Health Survey (SF-12v2). Internal consistency and testretest reliability were assessed using Cronbach's a coefficient and intra-class correlation coefficient, respectively. Sensitivity was determined by performing known-group comparisons by independent t test. Results FACT-P subscale scores had a moderate correlation with the corresponding SF-12v2 domain score that conceptually measures the similar construct providing evidence for adequate construct validity. Internal consistency was acceptable (a: 0.687-0.900) for all subscales aside from the Prostate Cancer Subscale (a: 0.505) and Trial Outcome Index (a: 0.562). FACT-P subscale and total scores showed good test-retest reliability (range 0.753-0.913). All total scales and most of the subscales were sensitive in detecting differences between patients with different levels of functional impairment but not different cancer stages or levels of prostate-specific antigen.
Introduction
Prostate cancer is the second commonest cancer in adult males worldwide [1] . As patients with prostate cancer had poorer well-being [2] [3] [4] , assessment of health-related quality of life (HRQOL) can be used clinically to assist healthcare providers by identifying individuals who may be at risk of poor well-being, to help guide treatment planning and to evaluate the effectiveness of interventions [5] .
The Functional Assessment of Cancer Therapy-General (FACT-G) [6] is a well-established and validated instrument which has been widely used to measure HRQOL in cancer patients [7] [8] [9] . One limitation of the FACT-G is that it only evaluates generically the impact of cancer on HRQOL without the consideration of the specific impacts which cancer may have on HRQOL. In response to this, the Functional Assessment of Cancer Therapy-Prostate (FACT-P) was developed to more specifically capture the HRQOL relevant to prostate cancer patients. The FACT-P is a modification of the FACT-G to include a Prostate Cancer Subscale [10, 11] . However, there is still a lack of evidence on the psychometrics of the FACT-P in Chinese patients with prostate cancer.
Objective of the present study was to assess the validity, reliability and sensitivity of the FACT-P in Chinese patients with prostate cancer.
Methods

Subjects and setting
Convenience sampling of patients with histological proof of prostate cancer was recruited between May 2013 and January 2014 in a major teaching hospital in Hong Kong. Patients were excluded if they could not understand or speak Cantonese, refused to participate or were too ill to give consent.
Subjects who consented were subsequently asked to answer a structured questionnaire which consisted of the traditional Chinese version of FACT-P (version 4), the Chinese Hong Kong version of Short Form-12 Health Survey version 2 (SF-12v2) and questions on sociodemographics.
Clinical data for each subject including the undertaken androgen deprivation therapy, prostate-specific antigen (PSA) level, the stage of cancer as classified by 7th Edition of TNM American Joint Committee on Cancer and the Karnofsky Performance status (KPS) [12] , were retrieved from subject's medical record.
All subjects were contacted again through telephone within 2 weeks after their baseline interview to assess testretest reliability.
Study instruments
Functional Assessment of Cancer Therapy-Prostate (FACT-P)
The traditional Chinese version of FACT-P (version 4) is part of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System and has 39 items grouped into five subscales: seven items related to Physical Well-Being (PWB), seven items related to Social/Family Well-Being (SWB), six items related to Emotional WellBeing (EWB), seven items related to Functional WellBeing (FWB) and twelve items belonging to the Prostate Cancer Subscale (PCS). Individual subscale scores are calculated by summation of the valued item responses, with higher scores indicating better HRQOL. The PWB, FWB and PCS subscales are combined to yield the FACT-P Trial Outcome Index (TOI). The sum of PWB, SWB, EWB and FWB subscale scores gives the overall FACT-G score with a range from 0 to 108. The PCS score is combined with the overall FACT-G score to form the overall FACT-P score with a range from 0 to 156. The FACIT questionnaires has demonstrated good psychometric properties in Hong Kong cancer patients [13, 14] . The Chinese (HK) SF-12v2 has been validated and normed on the Hong Kong Chinese adults [15, 16] . The SF-12v2 has eight domain scales and two summary scales, with higher scores indicating better HRQOL.
Statistical analysis
The construct validity of the FACT-P was assessed using Spearman's correlation test against the SF-12v2 domain scores holding similar constructs. The internal consistency was assessed by Cronbach's alpha using a value C0.7 to indicate adequate internal consistency [17] . Test-retest reliability was assessed by examining the intra-class correlation coefficient (ICC) over the 2-week period. An ICC of C0.7 was used to indicate good reproducibility [18] .
The sensitivity of the FACT-P was determined by performing known-group comparisons by independent t test and effect size. Cohen's effect size was calculated as the difference between mean scores, divided by pooled SD. Known clinical groups were (1) early cancer stage I/II versus late cancer stage III/IV; (2) KPS B 80 versus KPS [ 80 and (3) PSA \ 10 ng/ml versus PSA C 10 ng/ ml. It was hypothesized that patients with more severe cancer staging, lower KPS, higher PSA level or androgen deprivation therapy were associated with poorer HRQOL as measured by the FACT-P instrument.
Data analyses were conducted using SPSS Windows 21.0 (IBM SPSS Inc, Chicago, IL, USA). P value \ 0.05 was statistically significant. 
Results
Baseline characteristics of study subjects and results of construct validity are shown in Tables 1 and 2 , respectively. It was observed that the PWB, SWB, EWB and FWB subscales had a moderate correlation (r 0.44-0.69) with the corresponding SF-12v2 subscale that conceptually held the similar construct.
The reliability of the FACT-P is shown in Table 3 . The Cronbach's alpha coefficient exceeded 0.7 in the PWB, SWB, EWB and FWB subscales. The Cronbach's alpha coefficients were just short of 0.7 in FACT-G and FACT-P total scale, still acceptable, according to Churchill's benchmark [19] . The ICCs of all subscales, FACT-G total scale, TOI and FACT-P total scale exceeded 0.7.
The sensitivity of the FACT-P in differentiating known clinical groups is shown in Table 4 . The FACT-P was not able to detect differences between patients with different cancer stages (I/II vs. III/IV) or patients with different PSA levels. Statistically significant differences were detected between patients with KPS B 80 and those with KPS [ 80 by PWB, SWB, FWB subscales, Prostate Cancer Subscale, FACT-G total scale, TOI and FACT-P total scale. Moreover, patients with androgen deprivation therapy had statistically worse FWB score than those without.
Discussion
This study reported the psychometric properties of the FACT-P in Chinese patients with prostate cancer. Of note, the present study was not the first one to report the results of psychometric testing of prostate cancer-specific HRQOL instrument among Chinese patients with prostate cancer.
This study contributed further insights into the floor and ceiling effects of the FACT-P, identifying that a significant ceiling effect was evident in the PWB and EWB subscales. One interpretation is that Physical Well-being and Emotional Well-being are not negatively affected by prostate cancer in our study population. A previous study conducted in Singapore also found a significant ceiling effect in PWB and EWB subscales in Chinese patients with gastric cancer [20] . Clinicians and researchers should therefore interpret the PWB and EWB subscale scores with caution, especially when evaluating interventions for patients with prostate cancer as interventions may appear to be ineffective due to the significant ceiling effects.
The PWB, SWB and FWB subscales, TOI, FACT-G and FACT-P total scale were able to differentiate patients with different degrees of functional impairment. These findings also revealed that there are moderate differences in HRQOL between patients with varying functional impairment. This finding was in line with a previous study which suggested that the level of functional impairment as measured by the KPS had a significant association with HRQOL [21] . Moreover, the FWB subscale score was able to differentiate patients treated with and without androgen deprivation therapy. The change in functional well-being due to androgen deprivation therapy was supported by previous studies [22] [23] [24] . The measure was not able to discriminate known clinical groups, by cancer staging or PSA level. It appeared that the stage of cancer and PSA level did not significantly affect the HRQOL of our study subjects with prostate cancer. This was contrary to a previous study of Chinese patients which found that patients with stage III/VI prostate cancer had poorer HRQOL in the physical functioning, role functioning and social functioning domains as measured by QLQ-C30 than those with stage I/II prostate cancer [25] . A further examination of the inter-relationships between known clinical groups and HRQOL is warranted.
In summary, the FACT-P demonstrated satisfactory psychometric properties in terms of validity, reliability and sensitivity in Chinese patients with prostate cancer. Our finding supported the applicability of the instrument to evaluate the HRQOL and its associations with clinical interventions on Chinese patients with prostate cancer.
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